

PRODUCT INFORMATION

Common Name	2857916, GSK2857916, J6M0, J6M0-mcMMAF, Unconjugated mAb
Conjugate	Unconjugated
Synonyms	CD269;TNFRSF17;BCM;BCMA
Applications	ELISA; Flow Cyt
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG1 - kappa
Reactivity	Human
Target	BCMA
Uniprot ID	Q02223
Description	Anti-BCMA (belantamab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.






Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µl/well) Human BCMA, mFc tagged protein ([getskuurl sku="PME100035"]) can bind Anti-BCMA Neutralizing antibody in a linear range of 0.64-80.0 ng/ml

